Gene expression profiling of breast cancer cells in response to gemcitabine: NF-κB pathway activation as a potential mechanism of resistance
- 13 October 2006
- journal article
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 102 (2), 157-172
- https://doi.org/10.1007/s10549-006-9322-9
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- In vivo Induction of Resistance to Gemcitabine Results in Increased Expression of Ribonucleotide Reductase Subunit M1 as the Major DeterminantCancer Research, 2005
- Gemcitabine in metastatic breast cancerExpert Review of Anticancer Therapy, 2005
- State-of-the-art chemotherapy for advanced non-small cell lung cancerSeminars in Oncology, 2004
- The systemic treatment of advanced and metastatic bladder cancerThe Lancet Oncology, 2003
- Role of NF-κB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell deathOncogene, 2003
- Gemcitabine in the treatment of advanced pancreatic cancer: A comparative analysis of randomized trialsSeminars in Oncology, 2002
- Inhibition of NF-κB sensitizes human pancreatic carcinoma cells to apoptosis induced by etoposide (VP16) or doxorubicinOncogene, 2001
- NF-κB AND REL PROTEINS: Evolutionarily Conserved Mediators of Immune ResponsesAnnual Review of Immunology, 1998
- Constitutive nuclear factor-kappaB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells.JCI Insight, 1997
- Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.Journal of Clinical Oncology, 1997